

## COMPANY SPOTLIGHT - RAMSAY HEALTH CARE

**Ramsay (RHC) is one of the world's largest private healthcare companies with >500 facilities across 10 countries including Australia, the UK, France, Scandinavia, and parts of Asia.**

The company employs more than 77,000 staff and treats 8.5 million patients per annum in its hospital and primary care clinics. RHC delivers a range of acute and primary healthcare services and caters for a broad range of health care needs from primary care to highly complex surgery, as well mental health care and rehabilitation.

RHC has strong relationships with governments in all jurisdictions that it operates in. This was evident with RHC providing supplementary support to public services in a number of regions as part of a COVID-19 response. This is expected to continue as extended elective surgery waiting lists from the pandemic are addressed, particularly in the UK and France.

Over 70% of RHC's workforce is female and therefore we were encouraged to see earlier this year RHC pledge allegiance with HESTA's 40:40 Vision campaign for at least 40% women in ASX200 executive roles by 2030.

### KPI

- >8 million patient admissions / visits



### RHC Sub-Goal Alignment:

**SDG 3.4:** Reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.



This Report has been prepared and issued by Melior Investment Management Pty Limited (ACN 629 013 896) (Melior) as the investment manager of the Melior Australian Impact Fund (Fund). The Trust Company (RE Services) Limited (ABN 45 003 278 831) is the responsible entity and issuer of units in the Fund. Melior is a Corporate Authorised Representative (No. 001274055) of Adamantem Capital Pty Limited (ACN 614 857 037, AFSL No. 492717). This information is general information only and is not intended to provide you with financial advice, and has been prepared without taking into account your objectives, financial situation or needs. You should consider the product disclosure statement (PDS) for the Fund, prior to making any investment decisions. The PDS and target market determination (TMD) can be obtained by calling +61 2 9004 6071 or visiting our website [www.meliorim.com.au](http://www.meliorim.com.au). If you require financial advice that takes into account your personal objectives, financial situation or needs, you should consult your licensed or authorised financial adviser. This information is only as current as the date indicated, and may be superseded by subsequent market events or for other reasons. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. All investments contain risk and may lose value.